Patents by Inventor Marjorie See Waters

Marjorie See Waters has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for preparing branched ribonucleosides from 1,2-anhydroribofuranose intermediates
    Patent number: 7339054
    Abstract: A process is provided for the preparation of branched-chain ribonucleosides of formula (I): from the 1,2-anhydroderivatives of formula (II). wherein PG is a hydroxyl protecting group, B is a purine or pyrimidine nucleobase, and R1 is C1-6 alkyl. The compounds of formula (I) are inhibitors of HCV polymerase useful in the treatment of HCV infection.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: March 4, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Feng Xu, Matthew M Bio, Cameron Cowden, Kimberly A. Petrillo, J. Michael Williams, Chunhua Yang, Marjorie See Waters
  • Process for preparation of integrin receptor antagonist intermediates
    Publication number: 20040030134
    Abstract: A novel process is provided for the preparation of chiral intermediates useful in the asymmetric syntheses of &agr;v&bgr;3 integrin receptor antagonists. Also provided are the enantiomerically enriched intermediates that are obtained from the process.
    Type: Application
    Filed: September 11, 2003
    Publication date: February 12, 2004
    Inventors: James Christopher McWilliams, Elizabeth Buck, Kan K. Eng, Guy R. Humphrey, Peter E. Maligres, Jess W. Sager, Marjorie See Waters
  • Amine salts of an integrin receptor antagonist
    Patent number: 6444680
    Abstract: Amine salts of 3-(2-methyl-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]-naphthyridin-2-yl)-nonanoic acid are potent antagonists of the integrin &agr;v&bgr;3 receptor and are useful for the prevention and/or treatment of osteoporosis and vascular restenosis, as well as conditions associated with excessive angiogenesis, such as macular degeneration, diabetic retinopathy, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth. The invention also relates to a process for the preparation of the novel salts as well as pharmaceutical compositions containing the salts and methods of using the salts. Also disclosed are 3(R)- and 3(S)-(2-methylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid in the form of a zwitterion trihydrate.
    Type: Grant
    Filed: November 29, 2001
    Date of Patent: September 3, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Guy R. Humphrey, Marjorie See Waters, Wei Xu
  • Amine salts of an integrin receptor antagonist
    Publication number: 20020065291
    Abstract: Amine salts of 3-(2-methyl-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]-naphthyridin-2-yl)-nonanoic acid are potent antagonists of the integrin &agr;v&bgr;3 receptor and are useful for the prevention and/or treatment of osteoporosis and vascular restenosis, as well as conditions associated with excessive angiogenesis, such as macular degeneration, diabetic retinopathy, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth. The invention also relates to a process for the preparation of the novel salts as well as pharmaceutical compositions containing the salts and methods of using the salts. Also disclosed are 3(R)- and 3(S)-(2-methylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid in the form of a zwitterion trihydrate.
    Type: Application
    Filed: November 29, 2001
    Publication date: May 30, 2002
    Inventors: Guy R. Humphrey, Marjorie See Waters, Wei Xu